Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis

References

• Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015;22:88–95.
   PubMed Web of Science ®Google Scholar
• Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015;22:116–122.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S76–S110.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant. 1996;11:461–467.
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Parfrey PS, et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med. 2000;109:1–8.
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Sehgal AR, Rahman M, et al. The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol. 2008;102:1668–1673.
   PubMed Web of Science ®Google Scholar
• Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs. 2005;65(Suppl 2):29–39.
   PubMedGoogle Scholar
• Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int. 2013;83:377–383.
   PubMed Web of Science ®Google Scholar
• Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:2199–2269.
   PubMed Web of Science ®Google Scholar
• Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol. 2002;13(Suppl 3):S190–S195.
   PubMedGoogle Scholar
• Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.
   PubMed Web of Science ®Google Scholar
• Viazzi F, Leoncini G, Pontremoli R. Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system High Blood Press Cardiovasc Prev. 2013;20:273–82.
   PubMedGoogle Scholar
• Ruilope LM. Chronic kidney disease: Blood pressure control in CKD – still a matter of debate. Nat Rev Nephrol. 2013;9:572–573.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol. 2010;6:319–330.
   PubMed Web of Science ®Google Scholar
• Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30–48.
   PubMed Web of Science ®Google Scholar
• Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13:1100–1108.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861–867.
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Perico N, Sangalli F, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol. 1999;276:F457–F466.
   PubMedGoogle Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.
   PubMed Web of Science ®Google Scholar
• Lewis E, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med. 2001;345:851–860.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978–2986.
   PubMed Web of Science ®Google Scholar
• Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30:485–501.
   PubMed Web of Science ®Google Scholar
• Shimamoto K; Ando K; Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.
   PubMed Web of Science ®Google Scholar
• Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–140.
   PubMed Web of Science ®Google Scholar
• Yasuda T, Endoh M, Suzuki D, et al. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens Res. 2013;36:240–246.
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026–2033.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Navarese E et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–2056
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1–e34.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://handbook.cochrane.org.
   Google Scholar
• Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (eds). Introduction to Meta-analysis. Chichester (West Sussex, UK): John Wiley & Sons, Inc; 2009.
   Google Scholar
• Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7:105–125.
   PubMed Web of Science ®Google Scholar
• Zinellu A, Sotgia S, Mangoni AA, et al. Effects of ramipril and telmisartan on plasma concentrations of low molecular weight and protein thiols and carotid intima media thickness in patients with chronic kidney disease. Dis Markers. 2016; 2016:1821596.
   PubMedGoogle Scholar
• Nakamura T, Inoue T, Suzuki T, et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res. 2008;31:841–850.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kanno Y, Takenaka T, et al. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res. 2005;28:415–423.
   PubMed Web of Science ®Google Scholar
• Sharma AM, Hollander A, Köster J. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol. 2005;63:250–257.
   PubMed Web of Science ®Google Scholar
• Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol. 2007;18:1889–1898.
   PubMed Web of Science ®Google Scholar
• Aranda P, Segura J, Ruilope LM, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis. 2005;46:1074–1079.
   PubMed Web of Science ®Google Scholar
• Uneda K, Tamura K, Wakui H, et al. Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease. Clin Exp Hypertens. 2016;38:738–743.
   PubMed Web of Science ®Google Scholar
• Kaneshiro Y, Ichihara A, Sakoda M, et al. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res. 2009;32:51–58.
   PubMed Web of Science ®Google Scholar
• Antlanger M, Bernhofer S, Kovarik JJ, et al. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Ann Med. 2017;49:525–533.
   PubMed Web of Science ®Google Scholar
• Woo KT, Choong HL, Wong KS, et al. Aliskiren and losartan trial in non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014;15:515–522.
   PubMed Web of Science ®Google Scholar
• Takenaka T, Seto T, Okayama M, et al. Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study. Am J Nephrol. 2012;35:416–423.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Inoue T, Sugaya T, et al. Renoprotective effect of telmisartan in patients with chronic kidney disease. Clin Exp Hypertens. 2008;30:662–672.
   PubMed Web of Science ®Google Scholar
• Crowe AV, Howse M, Vinjamuri S, et al. The antiproteinuric effect of losartan is systemic blood pressure dependent. Nephrol Dial Transplant. 2003;18:2160–2164.
   PubMed Web of Science ®Google Scholar
• Matsuda H, Hayashi K, Saruta T. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens. 2003;17:271–276.
   PubMed Web of Science ®Google Scholar
• Matsuda H, Hayashi K, Homma K, et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res. 2003;26:875–880.
   PubMed Web of Science ®Google Scholar
• Plum J, Bunten B, Nemeth R, et al. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol. 1998;9:2223–2234.
   PubMed Web of Science ®Google Scholar
• Tsygankova OV, Platonov D, Bondareva ZG, et al. Do early and late nephroprotective effects differ with different inhibitors of renin-angiotensin-aldosteron system in chronic heart failure patients? Eur Heart J. 2012;33(suppl. 1):808–809.
   PubMedGoogle Scholar
• Nakamura T, Fujiwara N, Kawagoe Y, et al. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest. 2010;40:790–796.
   PubMed Web of Science ®Google Scholar
• Sowers J, Giles T, Ofili E, et al. Intensive treatment with combination amlodipine/valsartan vs moderate therapy for hypertensive patients with diabetes or CKD uncontrolled on ARB monotherapy. J Hypertens. 2010;28(Suppl A):E295 (abstract PP.17.149).
   Google Scholar
• Praga M, Fernández Andrade C, Luño J, et al. Antiproteinuric efficacy of losartan in comparison with amplodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant. 2003;18:1806–1813.
   PubMed Web of Science ®Google Scholar
• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–615.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12–26.
   PubMed Web of Science ®Google Scholar
• Weir MR. Progressive renal and cardiovascular disease: optimal treatment strategies. Kidney Int. 2002;62:1482–1492.
   PubMed Web of Science ®Google Scholar
• Henry TY. Progression of chronic renal failure. Arch Intern Med. 2003;163:1417–1429.
   PubMedGoogle Scholar
• Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7:936–953.
   PubMed Web of Science ®Google Scholar
• Cheung AK, Rahman M, Reboussin DM, et al. Effects of Intensive BP Control in CKD. J Am Soc Nephrol. 2017;28:2812–2823.
   PubMed Web of Science ®Google Scholar
• van den Belt SM, Heerspink HJL, Gracchi V, et al. Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol. 2018;29:2225–2233.
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Kröpelin TF, Hoekman J, et al. Reducing albuminuria as surrogate endpoint (REASSURE) consortium. J Am Soc Nephrol. 2015;26:2055–2064.
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762.
   PubMed Web of Science ®Google Scholar
• Wright TJ Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
   PubMed Web of Science ®Google Scholar
• The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863.
   PubMed Web of Science ®Google Scholar
• Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2006;1:761–767.
   PubMed Web of Science ®Google Scholar
• Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–287.
   PubMed Web of Science ®Google Scholar
• Hamrahian SM. Management of hypertension in patients with chronic kidney disease. Curr Hypertens Rep. 2017;19:43.
   PubMed Web of Science ®Google Scholar
• Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. 1996;334:13–18.
   Google Scholar
• Anderson AH, Yang W, Townsend RR, et al. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med. 2015;162:258–265.
   PubMed Web of Science ®Google Scholar
• Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014; 64:588–597.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:830–837.
   PubMedGoogle Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1–S290.
   PubMed Web of Science ®Google Scholar
• Shimamatsu K, Onoyama K, Harada A, et al. Effect of blood pressure on the progression rate of renal impairment in chronic glomerulonephritis. J Clin Hypertens. 1985;1:239–244.
   PubMedGoogle Scholar
• Bergström J, Alvestrand A, Bucht H, et al. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol. 1985;25:1–6.
   Web of Science ®Google Scholar
• Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int. 1989;35:670–674.
   PubMed Web of Science ®Google Scholar
• Peralta CA, Norris KC, Li S, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).Arch Intern Med. 2012;172:41–47.
   PubMedGoogle Scholar
• Eliahou HE, Cohen D, Hellberg B, Ben-David A, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol. 1988;8:285–290.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant. 2006;21:1257–1262.
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–548.
   PubMed Web of Science ®Google Scholar
• Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011;13:452–455.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Klingbeil AU, Fleischmann EH, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038–3045.
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190–1198.
   PubMed Web of Science ®Google Scholar
• Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893–900.
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:1921–1926.
   PubMed Web of Science ®Google Scholar
• Takagi H, Yamamoto H, Iwata K, et al. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol. 2013;167:1443–1449.
   PubMed Web of Science ®Google Scholar
• Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282–287.
   PubMed Web of Science ®Google Scholar
• Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–2531.
   PubMed Web of Science ®Google Scholar
• Wapstra FH, Navis G, de Jong PE, et al. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol. 1996;4:47–52.
   PubMedGoogle Scholar
• Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828.
   PubMed Web of Science ®Google Scholar